Efficacy of pantoprazole compared with ranitidine in the treatment of gastroesophageal reflux disease: An open-labeled randomized parallel and longitudinal comparative trial

Pharmaca

Volumn 40, Issue 3-4, 2002, Pages 199-206

  Duvnjak, Marko ^a   Virović, Lucija ^a   Supanc, Vladimir ^a   Troskot, Branko ^a   Antić, Zoran ^a   Kovačević, Igor ^a   Hrabar, Davor ^a   Ljubičić, Neven ^a   Šimičević, Velimir N ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Gastroesophageal reflux disease; Pantoprazole; Ranitidine; Treatment

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ESOPHAGUS MUCOSA; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0036987165     PISSN: 00316857     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Castell, DO, Brunton SA, et al. Management algorithms for the primary care physician and the specialist. Pract. Gastroenterol., 1998;22:18.
2. Larsen R R. Gastroesophageal reflux disease. Postgrad Med 1997;101:181.
3. Duvnjak M, Simicevic VN, et al. Gastroesophageal reflux disease: current issue. Acta clin. Croat., 1998;37:99.
4. Eggleston A, Wigerinck A, et al, Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. Gut 1998;42:13.
5. De Vault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am. J. Gastroenterol. 1999;94:1434.
6. Berardi R R. Proton pump inhibition. An effective, safe approach to GERD management. Postgrad Med Spec. 2002:24.
7. Kromer W, Horbach S, Luhmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology 1999;59:57.
8. Jaspersen D, Diehl KL, et al. A comparison of omeprazole. Iansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. Aliment Pharmacol Ther 1998;12:49.
9. Kromer W. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Scand J Gastroenterol Suppl 2001;234:3.
10. Carro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials. Clin Ther 2001:3:998.
11. Fitton A, Wiseman L. Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996:1:460.
12. Leite LP, Johnston BT, et al. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Gastroenterol 1996;1:127.
13. Dettmer A, Vogt R, et al. Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis. Int Pharmacol Ther 1998:12:865.
14. Chiba N, deGara CJ et al. Speed of healing and symptom relief in grade II-IV gastroesophageal reflux disease; a meta-analysis. Gastroenterology 1997;112:1798.
15. Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996;8(Suppl 1):21.
16. Armstrong D, Pare P, et al. Symptom relief in gastroesophagel reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive oesophagitis or endoscopy-negative reflux disease. Am. J. Gastroenterol. 2001;96(10):2849-57.
17. Feldman M, Burton ME. Histamine2-recetor antagonists. Standard therapy for acid-peptic diseases (2). N Engl J Med 1990;323:1749.
18. De Vault KR, Castell DO. Current diagnosis and treatment of gastroesophageal reflux disease. Mayo Clin Pro. 1994;69:867.
19. Johnson DA. Medical therapy for gastroesophageal reflux disease. Am J Med 1992;92(Suppl 5A):88.
20. McCarty-Dawson D. Sue SO, et al. Ranitidine versus cimetidine in the healing of the erosive oesophagitis. Clin Ther 1996;18:1150.
21. Hetzel DJ, Dent J, Reed WD. Healing and relapse of severe peptic oesophagitis after treatment with omeprazole. Gastroenterology 1988;95:903.
22. Klinkenberg-Knol EC, Jansen JM, Festen HR Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1987;1:349.
23. Havelund T, Laursen LS, Skoubo-Kristensen E. Omeprazole and ranitidine in treatment of reflux oesophagitis: Double-blind comparative trial. Br Med J 1988;296:89.
24. Gallo S, Dibildox M et al. Clinical superiority of 40 mg pantorazole (PANTO) compared to 2x150 mg ranitidine (RANI) in the healing of reflux esophagitis (GERD II/111). Gastroenterology 1997;112(Suppl):A189.